Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Living Cell Technologies Limited
LCT
http://www.lctglobal.com
Biotechnology
26
424

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.06 $0.06 $0.06 $0.06 $0.06 616100 $0.00 ( 4.69% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Company Overview

Business Description
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL® for the treatment of type 1 diabetes and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease.
Strategy Analysis
--

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -6.8 -1.9 0.0% 0.0 0.0 0.0% 0.0%
2013 A -3.0 -0.8 0.0% 0.0 0.0 0.0% 0.0%
2012 A 5.7 1.7 0.0% 3.7 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
CSL (CSL) $42,714M 0.0899 0.3345 0.0817 32.0790 24.0380 22.2222 1.31% 1.73% 1.98%
Living Cell (LCT) $27M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast (MSB) $1,298M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $349M 0.0000 1.7120 0.3828 41.0326 15.1303 10.9420 0.00% 4.30% 5.94%
Sirtex Medical (SRX) $1,605M 0.2906 0.6080 0.5486 68.7651 42.7646 27.6157 0.49% 0.68% 1.02%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.58 0.00
Market 1.03 14.70 1.03 0.65
Sector 0.89 14.20 2.99 0.98

Directors

Name Position Start Date
Professor Robert Bartlett Elliott Executive Director 15/01/2004
Mr Robert Moyse Willcocks Non-Executive Director 29/03/2011
Mr Laurrie Hunter Non-Executive Director 25/08/2006
Dr Bernard Tuch Non-Executive Director 19/07/2011
Mr Roy James Austin Non-Executive Director, Non-Executive Chairman 25/02/2011

Management

Name Position
Ken Taylor Acting CEO
Kenneth (Ken) P Taylor Chief Executive Officer
Nicholas (Nick) John Victor Geddes Company Secretary
Robert Elliott Director, Clinical Research & Innovation
John Cowan Head of Finance & Administration

Substantial Shareholders

Holding Name
25,000,000 (7%) Otsuka Pharmaceutical Factory, Inc
24,150,408 (6.76%) Palmert Members Limited
24,150,408 (6.76%) Coalco International Limited
17,792,675 (4.98%) Persistency Private Equity Limited (formerly Prospector Limited)

Calendar of Events

Date Event
17 February 2016 Report (Interim)
16 October 2015 Report (Annual)
14 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.